# A Phase IIa, Single-arm, Open-label Clinical Study to Evaluate the Efficacy, Safety and PK of CVM-1118 in Combination With Sintilimab and TACE in Participants With Incurable/Non-metastatic HCC

> **NCT07521852** · PHASE2 · RECRUITING · sponsor: **TaiRx, Inc.** · enrollment: 40 (estimated)

## Conditions studied

- HCC - Hepatocellular Carcinoma

## Interventions

- **COMBINATION_PRODUCT:** CVM-1118 + Sintilimab + TACE

## Key facts

- **NCT ID:** NCT07521852
- **Lead sponsor:** TaiRx, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-31
- **Primary completion:** 2027-12-31
- **Final completion:** 2029-12-31
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-04-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07521852

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07521852, "A Phase IIa, Single-arm, Open-label Clinical Study to Evaluate the Efficacy, Safety and PK of CVM-1118 in Combination With Sintilimab and TACE in Participants With Incurable/Non-metastatic HCC". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07521852. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*